And MT-802 can reduce phosphorylation of BTK protein in tumor cells isolated from patients with C481S mutant chronic lymphocytic leukemia (CLL), while Ibrutinib cannot. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.